Y 20811

Drug Profile

Y 20811

Latest Information Update: 14 Oct 1994

Price : $50

At a glance

  • Originator Mitsubishi Pharma Corporation
  • Class Anti-ischaemics; Antiasthmatics; Antiplatelets; Vascular disorder therapies
  • Mechanism of Action Thromboxane A2 synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Arrhythmias; Asthma; Ischaemic heart disorders; Thrombosis

Most Recent Events

  • 14 Oct 1994 Discontinued-II for Thrombosis in Japan (PO)
  • 14 Oct 1994 Discontinued-II for Asthma in Japan (PO)
  • 14 Oct 1994 Discontinued-Preclinical for Arrhythmias in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top